Eyenovia (EYEN, Financial) has successfully concluded a $50 million private placement with accredited investors. This funding allows the company to acquire over one million HYPE tokens at an average cost of around $34 each. In line with its strategic goals, Eyenovia plans to launch its own network validator with the support of an ecosystem partner, aiming to bolster the Hyperliquid blockchain's activity and facilitate entry into HYPE staking opportunities.
The company is in the process of rebranding, pending board approval, which will involve changing its name to “Hyperion DeFi” and its ticker to “HYPD.” Meanwhile, Eyenovia continues to advance the development of its Optejet UFD device. Verification and validation are set to begin in the next month, keeping the company on track for FDA registration this September.
Additionally, Eyenovia is exploring partnerships for licensing its platform, initially targeting opportunities in over-the-counter lens rewetting and artificial tears. Chardan served as the exclusive placement agent for this financing transaction.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Eyenovia Inc (EYEN, Financial) is $160.00 with a high estimate of $160.00 and a low estimate of $160.00. The average target implies an upside of 2,753.27% from the current price of $5.61. More detailed estimate data can be found on the Eyenovia Inc (EYEN) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, Eyenovia Inc's (EYEN, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
